Penumbra (PEN) Competitors $236.44 -2.88 (-1.20%) Closing price 03:59 PM EasternExtended Trading$236.12 -0.32 (-0.14%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PEN vs. LNTH, ITGR, GEHC, PHG, ZBH, SOLV, SNN, STVN, GKOS, and BLCOShould you be buying Penumbra stock or one of its competitors? The main competitors of Penumbra include Lantheus (LNTH), Integer (ITGR), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Stevanato Group (STVN), Glaukos (GKOS), and Bausch + Lomb (BLCO). These companies are all part of the "medical" sector. Penumbra vs. Its Competitors Lantheus Integer GE HealthCare Technologies Koninklijke Philips Zimmer Biomet Solventum Smith & Nephew SNATS Stevanato Group Glaukos Bausch + Lomb Penumbra (NYSE:PEN) and Lantheus (NASDAQ:LNTH) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk. Which has more volatility & risk, PEN or LNTH? Penumbra has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Which has better earnings and valuation, PEN or LNTH? Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPenumbra$1.19B7.67$14.01M$1.06223.06Lantheus$1.53B3.67$312.44M$3.5223.09 Is PEN or LNTH more profitable? Lantheus has a net margin of 16.55% compared to Penumbra's net margin of 3.41%. Lantheus' return on equity of 36.99% beat Penumbra's return on equity.Company Net Margins Return on Equity Return on Assets Penumbra3.41% 11.14% 8.40% Lantheus 16.55%36.99%20.55% Do analysts recommend PEN or LNTH? Penumbra presently has a consensus target price of $305.07, indicating a potential upside of 29.02%. Lantheus has a consensus target price of $131.20, indicating a potential upside of 61.46%. Given Lantheus' stronger consensus rating and higher possible upside, analysts clearly believe Lantheus is more favorable than Penumbra.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Penumbra 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.88Lantheus 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor PEN or LNTH? In the previous week, Penumbra had 3 more articles in the media than Lantheus. MarketBeat recorded 10 mentions for Penumbra and 7 mentions for Lantheus. Lantheus' average media sentiment score of 1.51 beat Penumbra's score of 0.68 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Penumbra 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals have more ownership in PEN or LNTH? 88.9% of Penumbra shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 5.0% of Penumbra shares are owned by company insiders. Comparatively, 2.0% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryLantheus beats Penumbra on 10 of the 17 factors compared between the two stocks. Get Penumbra News Delivered to You Automatically Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEN vs. The Competition Export to ExcelMetricPenumbraMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$9.27B$6.83B$5.63B$20.83BDividend YieldN/A1.28%4.25%3.65%P/E Ratio223.0616.1720.5025.98Price / Sales7.6761.62423.7848.12Price / Cash82.9120.3636.0222.28Price / Book7.884.638.134.56Net Income$14.01M$174.76M$3.24B$995.22M7 Day Performance-4.53%-3.09%2.03%-0.86%1 Month Performance-7.75%0.10%8.29%4.16%1 Year Performance23.35%3.09%28.40%8.88% Penumbra Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PENPenumbra4.7429 of 5 stars$236.44-1.2%$305.07+29.0%+25.2%$9.27B$1.19B223.064,500LNTHLantheus4.539 of 5 stars$79.19-1.5%$130.50+64.8%-32.7%$5.48B$1.53B22.50700Positive NewsITGRInteger3.0116 of 5 stars$117.05-3.3%$145.00+23.9%-0.5%$4.08B$1.72B55.4711,000News CoverageGEHCGE HealthCare Technologies4.1236 of 5 stars$74.61-1.9%$88.27+18.3%-7.3%$34.16B$19.67B15.7153,000Positive NewsPHGKoninklijke Philips2.9935 of 5 stars$23.84-1.4%N/A-9.8%$22.96B$19.50B55.4466,678Analyst UpgradeZBHZimmer Biomet4.9378 of 5 stars$92.58-1.2%$111.33+20.3%-13.7%$18.32B$7.68B20.4817,000News CoverageAnalyst UpgradeGap UpSOLVSolventum0.6324 of 5 stars$76.24-2.9%$81.50+6.9%+51.2%$13.19B$8.25B35.3022,000Analyst UpgradeGap UpSNNSmith & Nephew SNATS3.0162 of 5 stars$29.95-1.1%$28.00-6.5%+5.8%$13.12B$5.81B13.8717,349STVNStevanato Group1.4359 of 5 stars€24.23-1.5%N/A+17.7%€7.34B€1.19B47.515,521Positive NewsGKOSGlaukos4.3177 of 5 stars$101.69-1.7%$134.67+32.4%-13.8%$5.81B$383.48M-42.91780Analyst ForecastBLCOBausch + Lomb3.0345 of 5 stars$13.83-0.4%$15.54+12.4%-14.3%$4.89B$4.83B-13.4313,500 Related Companies and Tools Related Companies Lantheus Competitors Integer Competitors GE HealthCare Technologies Competitors Koninklijke Philips Competitors Zimmer Biomet Competitors Solventum Competitors Smith & Nephew SNATS Competitors Stevanato Group Competitors Glaukos Competitors Bausch + Lomb Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PEN) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Penumbra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Penumbra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
